ARWR
ARROWHEAD PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$58.16
+1.22%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$58.66
From 52W high−35.08%
Volume1.36M
Market cap$8.22B
P/E (TTM)—
P/S (TTM)12.3x
Div yield—
Key dataNov 6, 2026
Open
$58.66
From 52W high
−35.08%
Volume
1.36M
Market cap
$8.22B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−55.9x
P/E (TTM)
—
RSI (14)
39.9
MomentumView details →
1D Return
+1.22%
YTD Return
−12.29%
SummaryUpdated Jun 1, 2026
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a clinical-stage biotechnology company founded in 1989 and headquartered in Pasadena, California. The company went public in 1993 and has evolved into a leading developer of RNA interference (RNAi) therapeutics for treating rare and complex diseases. Arrowhead has built a proprietary platform technology that enables targeted delivery of RNAi medicines to specific tissues and organs, with a robust pipeline spanning multiple therapeutic areas including cardiometabolic diseases, pulmonary disorders, muscular dystrophy, and central nervous system conditions.
Similar companies
Latest newsMore news →
ARROWHEAD PHARMACEUTICALS, INC. completed a refinancing with funds managed by Sixth Street LLC, retiring its existing $400 million facility at a $68 million discount to the contractual minimum repayment amount and establishing a new $400 million facility.3d agoARROWHEAD PHARMACEUTICALS, INC. announced that it will present clinical data at the American Heart Association, Inc. Scientific Sessions in Chicago on November 7, 2026.5d ago